Wearable Medical Devices: Regulatory Pathway Guide (FDA, EU MDR 2026)

The Wearable Medical Device Market in 2026

The global wearable medical devices market has grown explosively. Depending on the market definition and scope, estimates for 2025 range from $42.7 billion to $103 billion, with projections of $168–505 billion by 2030–2034 at CAGRs of 20–26%. North America dominates with approximately 45.7% of global market share.

The market spans a broad spectrum — from consumer fitness trackers that count steps to FDA-cleared continuous glucose monitors and ECG-capable smartwatches. This spectrum is exactly what makes the regulatory landscape complex: the same physical device (a wrist-worn sensor) may be a general wellness product, a regulated medical device, or something in between, depending entirely on its intended use and marketing claims.

In January 2026, the FDA updated its general wellness device policy, significantly expanding the range of physiological parameters that can be measured without triggering medical device regulation — as long as specific guardrails are met. This guide covers the complete regulatory framework for wearable medical devices in the US and EU as of 2026.

What Is a Wearable Medical Device?

A wearable medical device is a body-worn product that uses sensors, software, and connectivity to diagnose, monitor, treat, or prevent disease. The key regulatory question is not the technology itself but the intended use — what the manufacturer claims the device does.

The Wearable Spectrum

US Regulatory Framework (FDA)

FDA's 2026 General Wellness Policy

In January 2026, the FDA issued updated guidance on "General Wellness: Policy for Low Risk Devices" that significantly affects wearable devices. The guidance expands flexibility for products that estimate physiological parameters — including blood pressure, oxygen saturation, blood glucose, and heart rate variability — when intended solely for wellness uses.

Products qualify for enforcement discretion when they:

• Are non-invasive and not implanted

• Do not use higher-risk interventions or technologies

• Are not intended for disease diagnosis or treatment

• Are not intended to substitute for an FDA-authorized device

• Do not prompt specific clinical action or medical management

• Do not present clinically mimicking values unless appropriately validated

Products are likely regulated as medical devices when they:

• Reference specific diseases or conditions

• Provide diagnostic or predictive outputs

• Use clinical or medical terminology in marketing

• Claim "medical-grade" accuracy

• Function as a substitute for a regulated device

Critical insight: The same hardware can shift classification based entirely on marketing language, labeling, and how information is presented to users. Apple's Blood Pressure Insights feature, for example, was positioned as a wellness feature with explicit disclaimers that it is "not a medical device" and "not to diagnose or treat any condition."

FDA Regulatory Pathways for Wearable Medical Devices

Key FDA-Cleared Wearable Devices

As of early 2025, the FDA has cleared over 1,000 AI/ML-enabled medical devices, many of which are wearable or incorporate wearable-generated data.

FDA QMSR Requirements (Effective February 2026)

Since February 2, 2026, the FDA's Quality Management System Regulation (QMSR) has replaced the former Quality System Regulation (QSR, 21 CFR Part 820). QMSR incorporates ISO 13485:2016 by reference. Wearable device manufacturers must comply with QMSR requirements, including:

• Design controls appropriate for the device classification

• Risk management per ISO 14971

• Software lifecycle processes (IEC 62304 for software functions)

• Cybersecurity risk management for connected devices

• Complaint handling and MDR reporting

EU Regulatory Framework (EU MDR)

Classification Under EU MDR

Wearable medical devices are classified under EU MDR Annex VIII classification rules:

Most wearable medical devices fall into Class IIa or IIb under EU MDR, requiring Notified Body involvement.

Conformity Assessment Pathway

1. Determine classification under Annex VIII rules

2. Implement QMS per Article 10 and ISO 13485

3. Prepare technical documentation per Annex II and III

4. Conduct clinical evaluation per Article 61 (may include literature review and/or clinical investigation)

5. Engage a Notified Body for conformity assessment (Annex IX, X, or XI)

6. Obtain CE marking and EU Declaration of Conformity

7. Register in EUDAMED (mandatory from May 28, 2026)

8. Appoint EU Authorized Representative (EC-REP) if manufacturer is outside the EU

EU-Specific Considerations for Wearables

• AI Act interplay: MDCG 2025-6 clarifies how EU MDR and the AI Act interact for AI-based wearables classified as high-risk under the AI Act

• Cybersecurity: EU Cyber Resilience Act (CRA) applies to connected devices; NIS2 directive for healthcare infrastructure

• Data protection: GDPR compliance required for all health data processing

• DiGA pathway (Germany): Digital health applications (Class I or IIa) can receive reimbursement through the DiGA directory by demonstrating positive healthcare effects

• EUDAMED registration: Mandatory from May 28, 2026, with transition period until November 27, 2026

Key EU MDR-Certified Wearables

Classification Decision Framework

Is Your Wearable a Medical Device?

START → Does the device have a medical intended use?
  │
  ├── NO → General wellness product → FDA enforcement discretion / Not MDR device
  │         (must meet wellness policy guardrails)
  │
  └── YES → What does it do?
            │
            ├── Diagnoses or detects disease → Regulated medical device
            │                                 (FDA Class II; EU MDR IIa/IIb)
            │
            ├── Monitors a diagnosed condition → Regulated medical device
            │                                  (FDA Class II; EU MDR IIa)
            │
            ├── Tracks wellness metrics only → May qualify as general wellness
            │                                (check FDA 2026 guidance guardrails)
            │
            └── Treats a condition → Regulated medical device
                                     (FDA Class II/III; EU MDR IIb/III)

Marketing Claims: The Deciding Factor

The same hardware with different marketing becomes a different regulatory product:

Technical Standards for Wearable Medical Devices

For connected wearables:

• IEC 62443: Industrial cybersecurity

• NIST Cybersecurity Framework: Recommended by FDA for premarket submissions

• HL7 FHIR: Health data interoperability standard

Clinical Evidence Requirements

FDA Expectations

EU MDR Expectations

• Class IIa: Clinical evaluation based on literature and/or clinical investigation

• Class IIb: More comprehensive clinical evaluation; clinical investigation often expected

• Clinical investigation plan per ISO 14155 if primary clinical data needed

• PMCF plan required as part of post-market surveillance

Market Data and Key Players

Market Size

Key Players

Key Market Developments (2024–2026)

• July 2025: Samsung acquired Xealth to integrate wearable wellness data into clinical workflows

• November 2024: Dexcom partnered with Oura to distribute the Oura Ring through health programs covering 75 million participants

• September 2024: Apple introduced Watch Series 10 with sleep apnea alerts and enhanced sensing

• February 2024: Samsung obtained FDA De Novo clearance for Galaxy Watch sleep apnea detection

• 2024: Dexcom Stelo became the first OTC CGM cleared by FDA

• 2025: Abbott FreeStyle Libre portfolio reached nearly $8 billion in annual Diabetes Care revenue, with the Libre 3 Plus offering 15-day wear life

Post-Market Requirements

FDA

EU MDR

FAQ

Does my fitness tracker need FDA clearance? If it only tracks general wellness metrics (steps, sleep duration, basic heart rate) without making medical claims, it does not need FDA clearance under the 2026 general wellness policy. However, any claim about diagnosing, treating, or managing a specific condition triggers regulation.

What changed in the FDA's 2026 wellness guidance? The 2026 update expanded the range of physiological parameters (blood pressure, SpO2, blood glucose, HRV) that can be measured by wearable products under enforcement discretion, as long as outputs are used only for wellness and meet specific guardrails. Previously, measuring these parameters was more likely to trigger medical device classification.

Do I need a 510(k) for a wearable ECG? Yes. Wearable ECG devices are regulated as Class II medical devices and typically require 510(k) clearance. The Apple Watch ECG, for example, was cleared via the De Novo pathway as a Class II device.

How do I position my wearable to avoid FDA regulation? Ensure all marketing materials, labeling, and user-facing communications avoid clinical/medical claims, disease-specific references, and claims about diagnostic accuracy. Include clear disclaimers that the product is for wellness purposes only. Consult the FDA's 2026 general wellness guidance for the complete list of guardrails.

What about wearable apps — are they regulated separately? Software functions on wearables are evaluated as part of the device if they contribute to the medical intended use. Standalone health apps may fall under the FDA's Clinical Decision Support (CDS) guidance or the general wellness policy. See our guides on SaMD and FDA CDS for more detail.

How does the EU MDR treat wearables differently from the US? EU MDR tends to classify more wearable features as medical devices compared to FDA's general wellness policy. The EU does not have an equivalent to FDA's enforcement discretion for general wellness products. If your wearable makes any health claims, it likely needs CE marking under EU MDR.